TY - JOUR T1 - Sustained virological response: a milestone in the treatment of chronic hepatitis C JF - World J Gastroenterol Y1 - 2013 A1 - Morisco, F. A1 - Granata, R. A1 - Stroffolini, T. A1 - Guarino, M. A1 - Donnarumma, L. A1 - Gaeta, L. A1 - Loperto, I. A1 - Gentile, I. A1 - Auriemma, F. A1 - Caporaso, N. KW - Adult KW - Aged KW - Antibodies KW - Antiviral Agents KW - Biological Markers KW - Biopsy KW - blood KW - Carcinoma KW - complications KW - Death KW - diagnosis KW - drug effects KW - drug therapy KW - Drug Therapy,Combination KW - eradication KW - Female KW - Fibrosis KW - Follow-Up Studies KW - genetics KW - growth & development KW - HCV KW - Hepacivirus KW - hepatitis KW - Hepatitis C KW - Hepatitis C Antibodies KW - hepatitis C virus KW - Hepatitis C,Chronic KW - Hospitals,University KW - Humans KW - immunology KW - Incidence KW - Infection KW - interferon KW - Interferon-alpha KW - Italy KW - Liver KW - Liver Cirrhosis KW - Male KW - methods KW - Middle Aged KW - Mortality KW - Patients KW - peginterferon KW - peginterferon alfa-2b KW - pegylated KW - Polyethylene Glycols KW - Prognosis KW - Proteins KW - Recombinant Proteins KW - Recurrence KW - Remission Induction KW - Ribavirin KW - Risk KW - Rna KW - Rna,Viral KW - Serum KW - Survival KW - Survival Rate KW - SVR KW - therapeutic use KW - therapy KW - Time Factors KW - treatment KW - Treatment Outcome KW - Viral Load KW - virology KW - Young Adult VL - 19 SP - 2793-2798 IS - 18 N1 - PMC3653153 ER -